Scientific Advisory Board

Daniel D. Von Hoff, M.D., F.A.C.P.

Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician-in-Chief and Distinguished Professor at Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He is also a Professor of Medicine, Mayo Clinic. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. He became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio.

Dr. Von Hoff was the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and later became the director of the Cancer Center and professor of medicine at the University of Arizona. In addition Dr. Von Hoff was a founder of Ilex Oncology which obtained FDA approval for 2 new anticancer agents – alemtuzumab and clofarabine. Ilex was sold to Genzyme Corporation for $1 billion.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, nab-paclitaxel, lapatinib, vismodegib, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

He has served a six-year term on President Bush's National Cancer Advisory Board. Von Hoff is a past president of the American Association for Cancer Research, was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians. He is the founder of Investigational New Drugs - The Journal of New Anticancer Agents and founder and Editor-in-Chief of Molecular Cancer Therapeutics. He was the associate editor for two AACR journals, Clinical Cancer Research and Cancer Research.

Recent honors include: first recipient of the Lori Groetken Memorial Lecture and Award – Washington University in St. Louis; Donald Buffmire, MD, FACP Award for Excellence in Translational Research, the Lifetime Achievement Award from US Oncology Research; and the Karnofsky Award – the highest award for the clinical research from the American Society of Clinical Oncology.

Waun Ki Hong, M.D.

Waun Ki Hong, M.D., is a leading authority on head, neck and lung cancers and one of the founders of cancer chemoprevention. Dr. Hong is Head of the Division of Cancer Medicine and Professor of Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He is an American Cancer Society Professor and holds the Samsung Distinguished University Chair in Cancer Medicine.

Beginning in the early 1980's, Dr. Hong's organ preservation research established new treatment standards that have enormously improved the quality of life for advanced laryngeal cancer patients. His seminal chemoprevention research has clearly shown that high-dose retinoids can reverse oral carcinogenesis—a proof of principle that has led to a new paradigm for cancer chemoprevention. He continues an active research program in chemoprevention with multiple clinical trials, and his molecularly-targeted approaches have the potential to significant improve the morbidity and mortality of head/neck cancer and lung cancers. Dr. Hong's research offers the possibility that cancer can be indefinitely delayed and possibly prevented, thus offering patients many more healthy years of life.

Dr. Hong is the recipient of numerous national and international awards including AACR's Joseph A. Burchenal and Rosenthal Foundation Awards, ASCO's David Karnofsky Award, and a prestigious American Cancer Society Clinical Research Professorship. He also served as president of AACR in 2001. More recently, he received the AACR/Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research and is currently an elected member of the ASCO Board of Directors.

In addition to his research and clinical work, Dr. Hong has played a pivotal role in shaping public policy. He was a member of the Advisory Committee to the Director of the NCI from 1997-2002 and chaired the Prevention, Clinical, and Therapeutic Subcommittee for the Extramural Board of Scientific Advisors (BSA) of the NCI from 1996-2002, and has served as an advisor for numerous other national organizations. He has trained and nurtured hundreds of young physicians and scientists from around the world, and has played an active role in increasing international collaborations in cancer research.

President George W. Bush appointed Dr. Hong to the National Cancer Advisory Board (NCAB) in 2008. Dr. Hong will serve a six-year term through March 9, 2014. The function of the NCAB is to advise, assist and make recommendations to the secretary of the Department of Health and Human Services and the director of the National Cancer Institute. The NCAB may also make recommendations regarding support grants and cooperative agreements, technical and scientific peer review.

Bruce D. Cheson, M.D., FACP, FAAS

Bruce D. Cheson, M.D., FACP, FAAS is Professor of Medicine, Head of Hematology and Deputy Chief of Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center. He attended the University of Virginia and then Tufts University Medical School and completed his internship and residency in Internal Medicine at the University of Virginia Hospitals. Dr. Cheson completed a clinical and research fellowship in Hematology at New England Medical Center Hospital and was Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Utah. From 1986-2002, he was Head, Medicine Section, CTEP at the National Cancer Institute.

Dr. Cheson is a recognized leader and expert in the field of lymphoma and other hematological malignancies and has authored over 400 medical publications and abstracts and contributed to over 60 textbooks. He is on the editorial board of numerous journals and was formerly Associate Editor of the Journal of Clinical Oncology. He is Editor-in-Chief of Clinical Advances in Hematology and Oncology. He has also been the editor of the American College of Physician's Medical Knowledge Assessment Program in Oncology and the ASCO SEP. He has served on several committees of the American Society of Clinical Oncology and was on its Board of Directors, and edited ASCO News and ASCO Daily News. From 2002-2006, he was on the Oncologic Drug Advisory Committee to the U.S. Food and Drug Administration. From 2003-2013 he chaired the Lymphoma Committee of the Cancer and Leukemia Group B and is the current chair of the AJCC Subcommittee on Lymphoma. He is on the Scientific Advisory Board of the Lymphoma Research Foundation and was its Chair from 2010-2012.

Dr. Cheson's clinical interests focus on the development of new therapeutic approaches for hematologic malignancies and standardizing methods of staging and evaluation of response to treatment, including his authorship of the well-known industry standard, "The Cheson Criteria".

Robert R. Ford, M.D.

Robert R. Ford, M.D. is a Clinical Instructor in the Department of Diagnostic Radiology at the Robert Wood Johnson Medical School. He is a consultant radiologist on staff at Carrier Clinic and Princeton University, and is a Senior Attending Radiologist at the University Medical Center at Princeton. Dr. Ford is certified by the National Board of Medical Examiners. He is board certified in Diagnostic Radiology and has a certificate of added qualifications in Neuroradiology from the American Board of Radiology.

Dr. Ford received his B.S. degree from Rutgers University in 1979 and his M.D. degree from Robert Wood Johnson Medical School in 1983. He completed an internship in Internal Medicine at Robert Wood Johnson University Medical Center and University Medical Center at Princeton. From 1984 to 1988 he completed a residency in Diagnostic Radiology at Cornell University Medical Center-New York Hospital, Memorial Sloane Kettering Cancer Center, and the Hospital for Special Surgery.

He joined Princeton Radiology Associates (PRA) in 1988. In 1998, Dr. Ford founded RadPharm, an Imaging Core Lab dedicated to the Independent Review of Diagnostic Imaging studies for the Pharmaceutical and Regulatory Agencies, primarily the United States Food and Drug Administration (USFDA). Between 1998 and 2008, while still a member of PRA, Dr Ford functioned as President and Chief Medical Officer (CMO) of RadPharm. In the capacity as CMO, Dr. Ford was a reviewer or supervised the independent radiologic review of images from no fewer than 295 clinical trials involving tens of thousands of patients primarily in the oncology therapeutic area. In addition during that time he worked with the USFDA and Pharmaceutical Companies for the approval of Herceptin, Eloxatin, Velcade, Sutent, Vectibix, Ixempra, Treanda, Doxil, Avastin and Pegloticase.

Dr. Ford is an author of the Response Evaluation Criteria of Solid Tumors (RECIST 1.1), an internationally accepted Response Criteria that is used to standardize patient response to therapy.

David Sidransky, M.D.

David Sidransky, M.D. is a renowned oncologist and research scientist named and profiled by TIME magazine as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.

Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the field of oncology, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. David is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the Chairman of Alfacell Corporation and serves on the Board of Directors of Xenomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others.

Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Award from the American Association of Cancer Research.

Manuel Hidalgo M.D., Ph.D.

Manual Hidalgo is the Vice Director of Translational Research, Clinical Research Program Director and Head of Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) and Director at the Centro Integral Oncologico Clara Campal (CIOCC). In addition he is a professor of Oncology at the University CEU San Pablo. Dr. Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialized in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programs.

He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the Pancreatic Cancer Research Team (PCRT) - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment.

He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer.

Recently appointed Director of Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC). Currently Head of Gastrointestinal Cancer Clinical Research Unit at the Centro Nacional de Investigaciones Oncologicas. Founding member of the Pancreatic Cancer Research Team (PCRT). He has participated in the clinical development of more than 30 novel anticancer agents.

Ken Miles, MD

Ken Miles is dually accredited in Radiology and Nuclear Medicine having undergone specialist training at Leicester and Cambridge UK. Obtaining his MD from the University of Leicester for a thesis on imaging of tissue perfusion with CT, he has subsequently pioneered the use of perfusion CT in oncology.

Ken has previously held clinical and academic posts in the UK and Australia. Currently, he undertakes clinical work in Radiology and Nuclear Medicine in Australia while his academic work is based at University College London, UK where he holds the position of Professorial Research Associate in the Institute of Nuclear Medicine. He is also the former Clinical Director of TexRAD, a company that is developing texture analysis software to provide imaging biomarkers for oncology.

Ken's scientific interests lie in research and clinical applications of imaging biomarkers in cancer, ranging from the development of new techniques through to demonstrating cost-effectiveness. He has wide experience in Positron Emission Tomography, having been involved in the establishment of three PET centres worldwide and recently completing a term as co-lead of the UK National Cancer Research Institute's PET Research Network. He has authored or co-authored more than 100 peer-reviewed scientific publications and contributed to or edited 11 books in Radiology